All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
On May 17, 2021, it was announced that the first patient has been dosed in China in a phase II trial (NCT04202003) combining lemzoparlimab with azacitidine in patients with newly diagnosed acute myeloid leukemia (AML) who are intolerant to intensive chemotherapy or treatment-naïve patients with intermediate- and high-risk myelodysplastic syndromes (MDS). The cohort expansion study will evaluate the safety, tolerability, and clinical efficacy of this promising combination.
CD47 is overexpressed on the surface of leukemic cells and it protects these cells by delivering a "don't eat me" signal to otherwise cell-engulfing macrophages. Lemzoparlimab, is a differentiated anti-CD47 monoclonal antibody that blocks this signal, hence enabling macrophages to attack leukemic cells appropriately. Azacitidine is a well-established chemotherapeutic drug that is often administered in combination with other agents to achieve greater synergistic efficacy in treating hematologic malignancies.
Results from preclinical studies and a phase I clinical trial have demonstrated strong anti-leukemic activity of lemzoparlimab combined with azacitidine, as well as a simultaneous reduction in the inherent binding to normal red blood cells, potentially limiting serious side effects such as severe anemia.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?